Astria Therapeutics Inc (NASDAQ: ATXS) kicked off on Friday, down -5.36% from the previous trading day, before settling in for the closing price of $6.53. Over the past 52 weeks, ATXS has traded in a range of $3.56-$12.92.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
During the last 5-year period, the sales growth of Healthcare Sector giant was 34.65%. While this was happening, its average annual earnings per share was recorded -24.28%. With a float of $45.29 million, this company’s outstanding shares have now reached $56.43 million.
Astria Therapeutics Inc (ATXS) Insider Activity
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Astria Therapeutics Inc is 19.75%, while institutional ownership is 82.82%.
Astria Therapeutics Inc (ATXS) Earnings and Forecasts
In the latest quarterly report, which was put into the public domain on 9/30/2024, the organization reported -0.42 earnings per share (EPS), higher than consensus estimate (set at -0.42) by 0. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.54 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -24.28% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will plunge by -8.47% during the next five years compared to 34.65% growth over the previous five years of trading.
Astria Therapeutics Inc (NASDAQ: ATXS) Trading Performance Indicators
Take a look at Astria Therapeutics Inc’s (ATXS) current performance indicators. Last quarter, stock had a quick ratio of 14.89.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.03, a number that is poised to hit -0.42 in the next quarter and is forecasted to reach -2.24 in one year’s time.
Technical Analysis of Astria Therapeutics Inc (ATXS)
Looking closely at Astria Therapeutics Inc (NASDAQ: ATXS), its last 5-days average volume was 0.22 million, which is a drop from its year-to-date volume of 0.35 million. As of the previous 9 days, the stock’s Stochastic %D was 31.76%.
During the past 100 days, Astria Therapeutics Inc’s (ATXS) raw stochastic average was set at 69.31%, which indicates a significant increase from 8.11% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.41 in the past 14 days, which was higher than the 0.41 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $6.37, while its 200-day Moving Average is $6.73. However, in the short run, Astria Therapeutics Inc’s stock first resistance to watch stands at $6.48. Second resistance stands at $6.79. The third major resistance level sits at $6.98. If the price goes on to break the first support level at $5.98, it is likely to go to the next support level at $5.79. Should the price break the second support level, the third support level stands at $5.48.
Astria Therapeutics Inc (NASDAQ: ATXS) Key Stats
The company with the Market Capitalisation of 348.77 million has total of 56,435K Shares Outstanding. Its annual sales at the moment are 0 K in contrast with the sum of -94,260 K annual income. Company’s last quarter sales were recorded 0 K and last quarter income was -33,050 K.
